The life sciences job market recovery didn't happen all at once. It began with pharmaceutical manufacturing in 2024, followed by testing labs in 2025, and only recently reached biotech R&D in 2026. This sub-sector-led turnaround provides a nuanced view of the market's health.
Contrary to popular belief, recent life sciences employment growth (2024-2025) was strongest not in the "Big Three" hubs, but in markets like Chicago, NYC, and Los Angeles. Meanwhile, the Bay Area and Boston experienced continued declines, challenging assumptions about where the industry is expanding.
CBRE's research shows a strong correlation where changes in venture capital funding for life sciences predict employment trends 9 to 18 months later. With VC funding up 33% in the first half of the year, a sustained increase in hiring is expected, providing a clear forecasting model for talent and space planning.
Despite a clear uptick in life sciences hiring and venture funding, the commercial real estate market for labs remains overbuilt with the highest vacancy rates ever recorded. This significant lag indicates that the positive momentum in talent has not yet translated into increased demand for physical space.
After years of steady growth, the latest academic data shows a decline in both the absolute number and the relative share of US students pursuing life sciences degrees. This trend signals a potential future challenge for the industry's talent pipeline, even as student interest shifts toward bioinformatics.
In CBRE's rankings, markets like New York/New Jersey and Los Angeles are rated higher than San Diego as optimal talent pools. This is not due to higher talent concentration, but the massive, absolute number of graduates and existing professionals that these larger metro areas produce.